Respiration; international review of thoracic diseases · 2026
Sex Differences in IPF: Data from the German INSIGHTS Registry.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Leuschner Gabriela, Prasse Antje, Klotsche Jens, Kreuter Michael, Wirtz Hubert, Pittrow David, Frankenberger Marion, Behr Jürgen
Аннотация
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) preferentially occurs in male patients and controversial results in gender-specific differences including overall mortality have been reported.
METHODS: The INSIGHTS-IPF registry was a non-interventional, prospective cohort study including IPF patients from 20 interstitial lung disease expert centers in Germany. Sex-related disparities were analyzed regarding comorbidities, clinical course, and survival.
RESULTS: Of the 1,043 IPF patients included, 842 (80.7%) were male and 201 (19.3%) were female. Male patients were more likely to have a history of smoking (p < 0.001) and environmental exposure, especially metal dust, wood dust, and solvents (p = 0.032). While males at baseline had a higher prevalence of coronary artery disease, atrial fibrillation, emphysema, and obstructive sleep apnea syndrome, in females, gastro-esophageal reflux disease and depression or depressive disorders were more frequent. Female IPF patients had more frequently a history of immunosuppressive therapy (p = 0.003). Regardless of gender, the INSIGHTS-IPF cohort as a whole showed a progressive worsening of lung function parameters over time. All-cause mortality did not differ between females and males (HR: 0.81; 95% CI: 0.63-1.04; p = 0.093) and female gender was not a significant predictor for mortality in IPF (HR 0.74; 95% CI: 0.54-1.03; p = 0.071). Interestingly, the GAP score underestimated the observed 2-year and 3-year mortality in females in GAP stage II.
CONCLUSION: In the German INSIGHTS-IPF registry, no differences in lung function decline and survival could be observed between female and male patients with IPF, indicating differences between IPF cohorts from the USA and Europe.
METHODS: The INSIGHTS-IPF registry was a non-interventional, prospective cohort study including IPF patients from 20 interstitial lung disease expert centers in Germany. Sex-related disparities were analyzed regarding comorbidities, clinical course, and survival.
RESULTS: Of the 1,043 IPF patients included, 842 (80.7%) were male and 201 (19.3%) were female. Male patients were more likely to have a history of smoking (p < 0.001) and environmental exposure, especially metal dust, wood dust, and solvents (p = 0.032). While males at baseline had a higher prevalence of coronary artery disease, atrial fibrillation, emphysema, and obstructive sleep apnea syndrome, in females, gastro-esophageal reflux disease and depression or depressive disorders were more frequent. Female IPF patients had more frequently a history of immunosuppressive therapy (p = 0.003). Regardless of gender, the INSIGHTS-IPF cohort as a whole showed a progressive worsening of lung function parameters over time. All-cause mortality did not differ between females and males (HR: 0.81; 95% CI: 0.63-1.04; p = 0.093) and female gender was not a significant predictor for mortality in IPF (HR 0.74; 95% CI: 0.54-1.03; p = 0.071). Interestingly, the GAP score underestimated the observed 2-year and 3-year mortality in females in GAP stage II.
CONCLUSION: In the German INSIGHTS-IPF registry, no differences in lung function decline and survival could be observed between female and male patients with IPF, indicating differences between IPF cohorts from the USA and Europe.